Search Results

You are looking at 81 - 90 of 328 items for :

  • "ovarian cancer" x
  • Refine by Access: All x
Clear All
Full access

Monica Chase, Yihua Xu, Eleanor O Caplan, Nicole Myer, Sheetal Sheth, Brandon T Suehs, and Gboyega Adeboyeje

(≤50) within 90 days of new advanced lung, colorectal (CRC), breast, or ovarian cancer diagnoses. Methods : We used a retrospective cohort study design to analyze administrative claims data on older patients (65-89 years) enrolled in a national US

Full access

Yunyun Liu, KKL Chan, and Hui Zhou

Purpose : Neoadjuvant chemotherapy (NACT) can reduce tumor burden, lower difficulty of surgery in advanced ovarian cancer. However, the option of NACT cycle is still highly controversial. This paper intends to explore whether the number of NACT

Full access

Qingqing Zhou, Chenchen Zhu, Zhen Shen, Jing Zhu, Tianjiao Zhang, Min Li, Jiwei Qin, Lili Qian, Chuan Chen, Hanyuan Liu, Zhihao Xu, Dabao Wu, Björn Nashan, and Ying Zhou

epithelial ovarian cancer treated in our hospital, between January 2017 and July 2019, and a comprehensive review of the medical documentation was performed to collect relevant data. We then analyze the related factors of the thrombosis in the EOC patients

Full access

excessive toxicity. Statistical analyses will focus on estimating overall response rates in patients with platinum-resistant ovarian cancer as stated in the primary objective. For the secondary objective, the Kaplan-Meier method will be used to estimate the

Full access

cancer research, the NCCN ORP also maintains a shared resources website and an informed consent database. For more information, visit NCCN.org/orp . NCCN Announces Projects to Improve Ovarian Cancer Care, With AstraZeneca NCCN Oncology Research Program

Full access

Laurie Elit, Gregory R. Pond, and Mark N. Levine

for results. Table 1 outlines some potential benefits and harms related to increased surveillance. Table 1. Potential Benefits Versus Harms of Surveillance Testing In the context of patients with advanced epithelial ovarian cancer, in a randomized

Full access

Filipa Lynce and Claudine Isaacs

Deleterious mutations in the BRCA1 and BRCA2 genes are associated with a markedly elevated risk of early-onset breast and ovarian cancer. Mutation carriers have up to a 70% risk of breast cancer and an 11% to 40% risk of ovarian cancer by age

Full access

Harold J. Burstein

,” and felt empowered by her choice. Thousands of women will similarly feel empowered and reassured by her remarks. For what it's worth, Jolie also received guideline-based care. As the daughter of a woman who had breast and ovarian cancer, Jolie met

Full access

Wylie Burke and Nancy Press

screening with MRI—what are the data for patients at high risk? N Engl J Med 2004 ; 351 : 497 – 500 . 11. Nelson HD Huffman LH Fu R Harris EL . Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility

Full access

-agent capecitabine, floxuridine, fluorouracil, and doxorubicin were removed. NCCN has published updates to the NCCN Guidelines for Ovarian Cancer. These NCCN Guidelines are currently available as Version 2.2011. Based on recent clinical trial data, the panel